MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
about
Cross talk of tyrosine kinases with the DNA damage signaling pathwaysTargeting the Checkpoint to Kill Cancer CellsCurrent and future trials of targeted therapies in cutaneous melanomaA haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity.Cell cycle checkpoint in cancer: a therapeutically targetable double-edged swordWee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomasBeyond angiogenesis blockade: targeted therapy for advanced cervical cancer.Functional kinomics identifies candidate therapeutic targets in head and neck cancerWEE1 tyrosine kinase, a novel epigenetic modifierTargeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in GlioblastomaCombined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenograftsWee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination RepairCombined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cellsIdentification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibitionMolecular targets and mechanisms of radiosensitization using DNA damage response pathways.Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision MedicineWee1 kinase as a target for cancer therapy.Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.Cell cycle proteins as promising targets in cancer therapyCombined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication.Emerging cell-cycle inhibitors for pancreatic cancer therapy.
P2860
Q26778614-DD2CC108-0D42-4686-9433-DC50A1D6CB05Q26795781-B210559C-D27C-4D7A-8A76-FA4DE15D53CEQ27022355-23F5A467-3061-41B4-AB74-248768F3577CQ27323300-0DD98EFD-B96E-4460-ADCA-351C46ECA5DAQ28078268-5064C89D-D438-4FA8-A815-48EF17112FCCQ28487835-1EF311FB-220B-4B9B-986E-AAF017426A61Q33917356-0F1CE6B7-5983-418E-9DA2-A0ED5E9E8A40Q34055936-822D2521-5E4D-4739-B1E9-C71F7E383653Q34335765-C78B784B-79B3-4E03-A2CB-12B7B03851F7Q34352858-27CB0C16-7EC9-4C98-B562-7B20931B2A4FQ34404877-511EC009-92F6-497F-BE09-2D807F0944BEQ34544769-26C9FAAD-1F9B-403C-9D22-533C362789BEQ34808616-FF74DE02-02BA-42E1-95F3-76523755471DQ35196526-8C81F60B-AE35-41D3-B668-399771E73350Q35287823-F812DC25-EB1E-420C-9E88-A5BA11D92C5CQ35463482-CEB46451-A1ED-40C6-9069-CAF701E38481Q35657004-1E3A3D78-1D7A-4597-AC91-913D257BD9E5Q35683131-ACEFC4CB-0212-4D2D-8FFA-7F788D96FF21Q35839058-BC35FE10-027E-4F21-8504-B0768D42D0E2Q36020559-CAD02CC8-F01B-497D-8983-A5538CB85D24Q36162494-1B9CD0EE-8B51-4DB3-8DD7-8FBEBF27C0E2Q36244669-EBA40D7B-F9A5-4E25-8F04-8514B2755E4BQ36309585-A4050789-90EB-4F33-A4A9-6DB96089C6B3Q36338764-9F422D18-B9F7-4864-AE54-EA4C53CF2C09Q36341628-F625C294-1102-4308-91A7-25340AC136A0Q36405766-6E120976-0850-400B-970F-EB97B9009492Q36454659-0CDDA51F-8BBA-40B7-A208-DC3BC361FA86Q36792626-34946BDF-D7A2-4076-9687-D15AF895C203Q36843733-71377303-40B7-45DF-B838-115DEF1C9965Q36971305-5AC08C00-8BFE-43A4-BC2D-A99862210CFBQ37075297-0AE9A974-E444-4FC4-A2C7-815D09BE13BCQ37230991-B955E673-714A-4677-81EB-0598EF9A9E8CQ37396839-9E7C0252-5B9E-4D94-8E2F-53EBD2794873Q37499287-E5963BC6-2AC4-4B0A-800B-1BFFF735A4B9Q37580332-419E6C78-35BF-46AE-B751-DEEBF9211E0DQ37692445-01647FC9-3F39-4E80-AC62-D68C4CD486BBQ37693690-E8A99254-82BD-4586-929C-61E6F9D8AEB2Q37706861-B37AF6B5-A14C-41AD-97C9-ED0B9D25E74DQ37936675-6EA9D503-7440-4C81-86E2-E0CD8A736E66Q38057759-B7F557EE-B878-4C1C-BB1E-8CE90DE74B3E
P2860
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
MK-1775, a small molecule Wee1 ...... nts, including 5-fluorouracil.
@en
MK-1775, a small molecule Wee1 ...... nts, including 5-fluorouracil.
@nl
type
label
MK-1775, a small molecule Wee1 ...... nts, including 5-fluorouracil.
@en
MK-1775, a small molecule Wee1 ...... nts, including 5-fluorouracil.
@nl
prefLabel
MK-1775, a small molecule Wee1 ...... nts, including 5-fluorouracil.
@en
MK-1775, a small molecule Wee1 ...... nts, including 5-fluorouracil.
@nl
P2093
P356
P1476
MK-1775, a small molecule Wee1 ...... nts, including 5-fluorouracil.
@en
P2093
Hidehito Kotani
Hiroshi Hirai
Junko Ohtani
Kazuhide Imagaki
Makiko Kobayashi
Megumu Okada
Naoko Sakai
Shinji Mizuarai
Takashi Yoshizumi
Takumi Sakai
P304
P356
10.4161/CBT.9.7.11115
P577
2010-04-01T00:00:00Z